Skip to main content

Table 4 Prognostic factors from series considering unselected populations and related survivals

From: Surgical treatment of liver metastases of gastric cancer: state of the art

Author year

Number

Timing

MST (months)

1-, 3-, 5-year survival rates

Prognostic factors

2008 [37]

58

Synchronous + metachronous

Overall: 16

No hepatic resection: 29.4%; 0%; 0%

 

Hepatic resection RFA: 75.3%; 31.7%; 20.8%

Ro resection

    

2009 [50]

72

Synchronous

NA

No hepatic resection: 36.4%; 0%; 0%

 

Hepatic resection (HAIC): 80%; 60%; 60%

H; P; R0 resection

    

2009 [51]

73

Metachronous

Overall: 7

  

BST: 5

     

Chemotherapy: 12

     

Hepatic resection: 23

BST: 22%; 2%; 0%

    

Chemotherapy: 45%; 6%; 0%

     

Hepatic resection; 81%; 20%; 20%

T; N; G of primary

    

R0 resection

     

2009 [52]

73

Synchronous

  

Stage of primary; H

Extrahepatic disease; treatment of mets

     

2010 [49]

 

Synchronous + metachronous

Overall: 16

  

Hepatic resection: 31.2

No hepatic resection: 53.2%; 4.2%; 0%

    

Hepatic resection: 82.3%; 46.4%; 37.1%